Hyperhomocysteinemia, ischemic stroke, and B-vitamin treatment: The jury is still out

Neurology India

Volumn 53, Issue 3, 2005, Pages 271-272

  Murthy, J M K ^a  

^a CARE HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AZAURIDINE; BILE ACID SEQUESTRANT; COBALAMIN; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; METHOTREXATE; METHYLMALONIC ACID; NICOTINIC ACID; PYRIDOXINE; VITAMIN B GROUP;

ALLELE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CYANOCOBALAMIN DEFICIENCY; DISEASE ASSOCIATION; DNA POLYMORPHISM; EDITORIAL; FOLIC ACID DEFICIENCY; GENE MUTATION; HUMAN; HYPERHOMOCYSTEINEMIA; RISK FACTOR; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

EID: 27344440789     PISSN: 00283886     EISSN: None     Source Type: Journal    
DOI: 10.4103/0028-3886.16920     Document Type: Editorial

References (24)

1. Hassan A, Markus HS. Genetics and ischemic stroke. Brain 2000;123:1784-812.
2. Goldstein L, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 2001;32:280-99
3. Sacco RL, Roberts JK, Jacobs BS. Homocysteine as a risk factor for ischemic stroke:an epidemiological story in evoluation. Neuroepidemiology 1998;17:167-73.
4. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocysteine and cardiovascular disease: a critcal review of the epidemiologic evidence. Ann Intern Med 1999;131:363-75.
5. Bostom AG, Rosenberg IH, Silbershatz H, Jacques PP, Selhub J, D'Agostino RB, et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med 1999;131:352-5.
6. Perry IJ. Homocysteine, hypertension and strke. J Hym Hypertens 1999;13:289-93.
7. Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risks of cardiovascular disease causal or casual? Arch Intern Med 2000;160:422-34.
8. Modi M, Prabhakar S, Majumdar S, Khullar M, Das P. Hyperhomocysteinemia as a risk factor for ischemic stroke:an India scenario. Neurol India 2005;53:271-2.
9. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.
10. Kelly PJ, Rosand J, Kistler JP, Shih VE, Silveira S, Plomaritoglou A, et al. Homocysteine, MTHFR 677C→T polymorphism, and risk of ischemic stroke: Results of a meta-analysis. Neurol 2002;59:529-36.
11. Cronin S, Furie KL, Kelly PJ. Dose-related association of MTHFR 677T allele with risk of ischemic stroke: Evidence from a cumulative meta-analysis. Stroke 2005;36:1581-7.
12. Wadia RS, Bandishti S, Karche M. B12 and folate deficiency: incidence and clinical features. Neurol India 2000;48:302-4
13. Alluri RV, Mohan V, Komandur S, Chawda K, Chaudhary JR, Hasan Q. MRHFR C677T gene mutation as a risk factor for arterial stroke: a hospital-based study. Euro J Neurol 2005;11:1-5.
14. Nappo P, De Rosa N, Marfella R, De Lucia D, Ingrosso D, Perna AF, et al. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999;281:2113-8.
15. Mudd SH, Finkelstein JD, Refsum H, Ueland PM, Malinow MR, Lentz SR, et al. Homocysteine and its disulfide derivatives: a suggested consensus terminology. Arterioscler Thromb Vasc Biol 2000;20:1704-6.
16. Frantzen P, Faaren AL, Alfheim I, Nordhei AK. Encyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin Chem 1998;44:311-6.
17. Malinow MR, Bostom AG, Krauss RM. Homocysteine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee. America Heart Association. Circuation 1999;99:178-82.
18. Diaz-Arrastia R. Homocysteine and neurologic disease. Arch Neurol 2000;57:1422-8.
19. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. BMJ 1998;316;894-8.
20. Toole JP, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-75.
21. Hankey GJ. Secondary prevention of recurrent stroke. Stroke 2005;36:218-21.
22. The VITATOPS Trial Study Group. The VITATOPS (Vitamins to Prevent, Stroke) Trial:Rationale and design of an international, large, simple, randomized trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischemic attack and stroke. Cerebrovasc Dis 2002;13:120-6.
23. Khanduri U, Sharma A, Joshi A. Occult cobalamin and folate deficiency in Indians. Natl Med J India 2005;18:182-3.
24. Allen RH, Stabler SP, Savage DG, Lindenbaum J. Diagnosis of cobalamin deficiency 1: Usefulness of serum methylmalonic acid and total homocysteine concentrations. Am J Hematol 1990;34:90-8.